Lisanti Capital Growth LLC Takes Position in PROCEPT BioRobotics Corporation $PRCT

Lisanti Capital Growth LLC bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 43,965 shares of the company’s stock, valued at approximately $2,532,000.

Other hedge funds have also bought and sold shares of the company. ANTIPODES PARTNERS Ltd bought a new stake in PROCEPT BioRobotics during the 1st quarter valued at $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of PROCEPT BioRobotics during the first quarter worth about $40,000. CWM LLC increased its position in shares of PROCEPT BioRobotics by 69.5% during the first quarter. CWM LLC now owns 873 shares of the company’s stock worth $51,000 after acquiring an additional 358 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of PROCEPT BioRobotics by 1,262.5% in the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after acquiring an additional 1,010 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in PROCEPT BioRobotics by 32.5% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $64,000 after acquiring an additional 270 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Trading Up 2.0%

NASDAQ PRCT opened at $31.92 on Friday. The business’s fifty day moving average is $36.02 and its 200-day moving average is $47.62. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.86. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -20.86 and a beta of 0.98. PROCEPT BioRobotics Corporation has a one year low of $29.78 and a one year high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The business had revenue of $83.33 million for the quarter, compared to analyst estimates of $80.78 million. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

PRCT has been the subject of a number of recent research reports. TD Cowen decreased their price objective on PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday. Truist Financial cut their target price on PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Wednesday, October 8th. Piper Sandler restated an “overweight” rating and set a $50.00 price objective (down from $55.00) on shares of PROCEPT BioRobotics in a research note on Wednesday. Finally, Leerink Partners reiterated an “outperform” rating and issued a $55.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.30.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).